RECURrence of Atrial Fibrillation after cardioversion of patients randomized to open-label treatment with dapagliflozin or usual care (RECUR-AF)

Phase 1

• Conditions: Atrial fibrillation; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: CTIS2024-513719-28-00
• Lead Sponsor: Karolinska University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-31
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 1600

Inclusion Criteria

Patients with AF on ECG who are planned for electrical cardioversion within 7-26 from inclusion-date., Age = 55 years., The subject has given their written consent to participate in the trial.

Exclusion Criteria

Current treatment with SGLT2 inhibitor (dapagliflozin, empagliflozin, canagliflozin, sotagliflozin)., Prior/current diagnosis of heart failure., Type 1 diabetes mellitus., Estimated glomerular filtration rate (eGFR) < 25 ml/min/1.73m2., Pulmonary vein isolation within last 3 months or planned pulmonary vein isolation within study period (56 days)., Contraindications to SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, sotagliflozin)., Any condition or circumstance in which the patient should not participate in the study according to the study investigator.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified